Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | AOC1 | P19801 | 3/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14525220 | 0.82 | HTR1A (0.32) | HTR1ANOS3NOS2USP2CYP1A2 | |
| SCHEMBL3929716 | 0.80 | CCR1 (0.43) | HTR6HTR1AUSP2CYP1A2CYP3A4 | |
| SCHEMBL2125060 | 0.74 | NOS3 (0.50) | NOS3NOS1NOS2 | |
| SCHEMBL5630218 | 0.72 | NOS3 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL17052905 | 0.72 | AOC1 (0.39) | AOC1AOC3 | |
| SCHEMBL13547616 | 0.72 | CCR1 (0.40) | HTR6NOS3NOS2USP2CYP1A2 | |
| SCHEMBL13343549 | 0.71 | NOS3 (0.32) | NOS3NOS1NOS2 | |
| SCHEMBL3936149 | 0.71 | BACE1 (0.31) | HTR1A | |
| SCHEMBL5631598 | 0.70 | NCF1 (0.45) | NOS3NOS2USP2CYP1A2CYP3A4 | |
| SCHEMBL21789944 | 0.68 | CYP3A4 (0.34) | USP2CYP1A2CYP3A4CYP2D6ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208603-B2 | Reducing amination with cyanohydrin | PIERRE FABRE MEDICAMENT (FR) | 2007-04-24 | — | — | US | claimed |
| EP-1358179-B1 | SYNTHESIS METHOD AND INTERMEDIATES OF PYRIDIN-2-YL-METHYLAMINE | PF MEDICAMENT (FR) | 2006-05-10 | — | — | EP | claimed |
| US-20040116705-A1 | Reducing amination with cyanohydrin | PIERRE FABRE MEDICAMENT (FR) | 2004-06-17 | — | — | US | claimed |
| EP-1358179-A1 | SYNTHESIS METHOD AND INTERMEDIATES OF PYRIDIN-2-YL-METHYLAMINE | PIERRE FABRE MEDICAMENT (FR) | 2003-11-05 | — | — | EP | claimed |
| WO-2002064585-A1 | SYNTHESIS METHOD AND INTERMEDIATES OF PYRIDIN-2-YL-METHYLAMINE | PIERRE FABRE MEDICAMENT (FR) | 2002-08-22 | — | — | WO | claimed |
| US-8168786-B2 | 1,2,4-triazole- 3,5-dione derivatives; for imaging and therapy of psychiatric, eating, sleeping, bipolar disorder; anxiolytic agent, antidepressant; Alzheimer's, Parkinson's diseases, epilepsy; imaging agents for a serotonin receptor | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168786-B2 | 1,2,4-triazole- 3,5-dione derivatives; for imaging and therapy of psychiatric, eating, sleeping, bipolar disorder; anxiolytic agent, antidepressant; Alzheimer's, Parkinson's diseases, epilepsy; imaging agents for a serotonin receptor | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-05-01 | — | — | US | disclosed |
| WO-2009006227-A1 | RADIOLABELED COMPOUNDS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20080138283-A1 | Radiolabeled compounds and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080138283-A1 | Radiolabeled compounds and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-06-12 | — | — | US | disclosed |
| US-7208603-B2 | Reducing amination with cyanohydrin | PIERRE FABRE MEDICAMENT (FR) | 2007-04-24 | — | — | US | disclosed |
| US-7208603-B2 | Reducing amination with cyanohydrin | PIERRE FABRE MEDICAMENT (FR) | 2007-04-24 | — | — | US | disclosed |
| US-7208603-B2 | Reducing amination with cyanohydrin | PIERRE FABRE MEDICAMENT (FR) | 2007-04-24 | — | — | US | disclosed |
| EP-1358179-B1 | SYNTHESIS METHOD AND INTERMEDIATES OF PYRIDIN-2-YL-METHYLAMINE | PF MEDICAMENT (FR) | 2006-05-10 | — | — | EP | disclosed |
| US-20040116705-A1 | Reducing amination with cyanohydrin | PIERRE FABRE MEDICAMENT (FR) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138283-A1 | Radiolabeled compounds and uses thereof | HTR5A, SLC18A2, HTR1A | HTR6 15/4885PDCD1 3610/4885CD274 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.